ASN 100

Drug Profile

ASN 100

Alternative Names: ASN-1 and ASN-2; ASN-100

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Arsanis Biosciences
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Staphylococcal infections
  • New Molecular Entity No

Highest Development Phases

  • Phase II Staphylococcal infections

Most Recent Events

  • 01 Dec 2016 ASN 100 receives Fast Track designation for Staphylococcal infections [IV,Infusion] (Prevention) in USA
  • 01 Nov 2016 Phase-II clinical trials in Staphylococcal infections (Prevention) in USA (IV) (NCT02940626)
  • 06 Sep 2016 Arsanis plans a phase II trial for Staphylococcal infections and Pneumonia (Prevention) in USA (IV, Infusion) (NCT02940626)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top